BioCryst Pharma soars 6.4% as Q2 results crush expectations

BioCryst Pharmaceuticals (BCRX) shares surged 6.4% after the company reported second-quarter 2025 adjusted earnings of $0.15 per share, significantly exceeding analyst estimates of $0.01, and revenue of $163.4 million, well above the $149.8 million consensus, driven by record sales of its hereditary angioedema treatment ORLADEYO. ORLADEYO net revenue reached $156.8 million, up 45% year-over-year, marking its highest-ever quarter for new patient prescriptions. While the company maintained its full-year ORLADEYO revenue guidance of $580-600 million, which is below the analyst consensus, it noted this projection accounts for the expected sale of its European business.

Analysis

BioCryst Pharmaceuticals (BCRX) reported a historically strong second quarter for fiscal year 2025, significantly outperforming market expectations. The company posted adjusted earnings of $0.15 per share, starkly contrasting with the consensus estimate of just $0.01, while revenue grew 50% year-over-year to $163.4 million, beating the $149.8 million forecast. This performance was primarily driven by the robust commercial momentum of its key asset, ORLADEYO, which generated $156.8 million in net revenue, a 45% increase from the prior year, and achieved a record number of new patient prescriptions. The company's operational leverage has notably improved, with operating income more than tripling to $29.8 million from $8.8 million in the same period last year. While the maintained full-year ORLADEYO revenue guidance of $580-600 million is below the analyst consensus of $608.4 million, this projection is strategically impacted by the anticipated sale of its European business, a crucial detail that mitigates concerns of a potential slowdown in organic growth. The company’s pipeline presents near-term catalysts, including a December 12 PDUFA date for a pediatric version of ORLADEYO and anticipated year-end data releases for two other clinical programs.

Key Decisions for Investors

• Investors should recognize the second-quarter results as a strong validation of BioCryst's commercial execution, with the significant earnings beat and record ORLADEYO sales signaling robust underlying demand.
• The full-year revenue guidance, while below consensus, should be contextualized by the planned divestiture of the European business, suggesting the core growth narrative remains intact.
• Monitor key upcoming catalysts for potential share price appreciation, specifically the December 12 PDUFA date for the ORLADEYO pediatric formulation and the year-end data readouts for BCX17725 and avoralstat.
• The sharp increase in operating income indicates a potential shift towards sustainable profitability, a critical metric for assessing the company's long-term investment case beyond its revenue growth.